Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
Date:2/13/2009

NEW YORK, Feb. 13 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an updated Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc. (BNC: TSX). The full 68-page report can be found at www.crystalra.com.

Bioniche Life Sciences Inc. ("Bioniche" or "the Company") is a Canadian biopharmaceutical company that aims to improve the quality of life in both humans and animals through innovative research, technologies, and therapeutics. To develop the proprietary platform technologies that the Company uses to create human and animal therapeutic agents, Bioniche is structured in three global business units: (1) Bioniche Therapeutics (Human Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety.

The Company's most advanced Human Health product candidate is Urocidin(TM), a treatment for non-muscle-invasive bladder cancer that entered Phase III clinical development in late 2006 after the U.S. Food and Drug Administration (FDA) granted Bioniche Fast Track status. A second Phase III trial is likely to begin under the FDA's Special Protocol Assessment (SPA) and Fast Track designations after the current Phase III trial is fully enrolled and when financing is available.

Bioniche Animal Health markets over 100 products globally, developing products that enhance reproductive performance in animals and reduce the animal health industry's reliance on antibiotics. With fiscal 2008 revenues of C$17.5 million, the line of reproductive products comprises Bioniche Animal Health's largest sales category. As a whole, the business unit had fiscal 2008 revenues of C$27.7 million. A lead Animal Health product is Folltropin(R)-V, a reproductive hormone that induces superovulation in cattle and sheep.

Bioniche Food Safety develops veterinary biopharmaceuticals to improve the safety of human food and water supplies. Its most significant initiative is Econiche(TM), a vaccine administered to cattle that reduces the level of Escherichia coli (E. coli) O157:H7 that cattle shed, thus minimizing the risk of human illness from contaminated food or water. The vaccine was fully licensed in Canada in October 2008. In addition, in mid-2008, the Company secured C$25 million in government funding for a vaccine production facility scale-up in Belleville, Ontario, Canada, as part of a long-term C$107 million project to create an Animal Health and Food Safety Vaccine Manufacturing Centre.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of sixty-two thousand five hundred U.S. dollars and one hundred fifty thousand Options/Warrants for its services in creating and updating the base report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with SEDAR.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Recombinant Human Renin - Crystallographic Grade
2. 3-D photonic crystals will revolutionize telecommunications
3. Researchers outline structure of largest nonvirus particle ever crystallized
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
6. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
7. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
9. Silicon photonic crystals key to optical cloaking, researchers say
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):